Biren Amin
Stock Analyst at Piper Sandler
(1.42)
# 3,409
Out of 4,944 analysts
62
Total ratings
42.59%
Success rate
-10.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Neutral | $11 → $15 | $18.80 | -20.21% | 11 | Jul 29, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $63 → $68 | $49.09 | +38.52% | 3 | Jul 14, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $1.64 | +265.85% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $0.68 | +488.24% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $6.04 | +181.46% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.03 | +579.61% | 3 | May 14, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $36.33 | +40.38% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $17.15 | +121.57% | 1 | Mar 31, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $35.90 | +111.70% | 1 | Mar 19, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $3.17 | +278.55% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $39.86 | +78.12% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $4 | $4.46 | -10.31% | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.96 | +290.63% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $9.91 | +111.91% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $72.50 | +58.62% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $23.90 | +33.89% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $4.81 | -37.63% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.48 | +20.24% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.41 | +4,864.54% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.37 | +13,680.06% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.35 | +348.60% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.91 | +1,068.38% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $7.44 | +6,620.43% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $6.41 | +118.41% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $556.56 | +24.16% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $1.86 | +437.63% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $20.09 | +402.74% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $128.89 | -46.47% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $387.77 | -60.03% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.76 | +7,627.27% | 4 | Mar 6, 2017 |
Sarepta Therapeutics
Jul 29, 2025
Maintains: Neutral
Price Target: $11 → $15
Current: $18.80
Upside: -20.21%
BridgeBio Pharma
Jul 14, 2025
Maintains: Overweight
Price Target: $63 → $68
Current: $49.09
Upside: +38.52%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $1.64
Upside: +265.85%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $0.68
Upside: +488.24%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $6.04
Upside: +181.46%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.03
Upside: +579.61%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $36.33
Upside: +40.38%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $17.15
Upside: +121.57%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $35.90
Upside: +111.70%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $3.17
Upside: +278.55%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $39.86
Upside: +78.12%
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $4.46
Upside: -10.31%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $8.96
Upside: +290.63%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $9.91
Upside: +111.91%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $72.50
Upside: +58.62%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $23.90
Upside: +33.89%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $4.81
Upside: -37.63%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $12.48
Upside: +20.24%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.41
Upside: +4,864.54%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.37
Upside: +13,680.06%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.35
Upside: +348.60%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $2.91
Upside: +1,068.38%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $7.44
Upside: +6,620.43%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $6.41
Upside: +118.41%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $556.56
Upside: +24.16%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $1.86
Upside: +437.63%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $20.09
Upside: +402.74%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $128.89
Upside: -46.47%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $387.77
Upside: -60.03%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.76
Upside: +7,627.27%